Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track KZIA with free AI briefings, catalyst countdowns, and dilution alerts.

KZIA · KAZIA THERAPEUTICS LTD

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$69.5M Cash on Hand
57.9mo Cash Runway
Follow KZIA by email Get an email when KZIA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about KZIA, unsubscribe in one click. Privacy

📣 What KZIA Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
TSP-1 Activator VT1021 Glioblastoma Phase 2/3 · NCT03970447 Recruiting
Dianhydrogalactitol (VAL-083) Glioblastoma Phase 2/3 · NCT03970447 Recruiting
Pegargiminase Glioblastoma Phase 2/3 · NCT03970447 Recruiting
ATM Kinase Inhibitor AZD1390 Glioblastoma Phase 2/3 · NCT03970447 Recruiting
Troriluzole Glioblastoma Phase 2/3 · NCT03970447 Recruiting
Tinostamustine Glioblastoma Phase 2/3 · NCT03970447 Recruiting
Paxalisib (GDC-0084) Glioblastoma Phase 2/3 · NCT03970447 Recruiting
PI3K Inhibitor paxalisib CDK Gene Mutation Phase 2 · NCT03994796 Active not recruiting
Metformin Glioblastoma Phase 2 · NCT05183204 Completed
Irinotecan Childhood Cancer Phase 1/2 · NCT06208657 Recruiting
Part B: Expansion Cohort of Cantrixil Ovarian Neoplasms Phase 1 · NCT02903771 Completed
Part A: Dose Escalation of Cantrixil Ovarian Neoplasms Phase 1 · NCT02903771 Completed
Idronoxil Unspecified Adult Solid Tumor, Protocol Specific Phase 1 · NCT00022295 Completed
VEGFR3 Inhibitor EVT801 Solid Tumor, Adult Phase 1 · NCT05114668 Completed
[14C]-Paxalisib Capsule Healthy Phase 1 · NCT05012670 Completed

Also used in these trials (approved or third-party drugs, not KZIA's own candidates): Lomustine, Temozolomide, Regorafenib, Abemaciclib, Trastuzumab, Nivolumab And Relatlimab-Rmbw, Entrectinib, Adagrasib.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

KZIA holds $69.5M in cash and short-term investments and burns about $3.6M/quarter from operations, an estimated runway of 57.9 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 35 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when KZIA files for a raise →

👥 Who Owns KZIA

Insiders 0% Other 5%+ holders 0.4% Institutions (54 holders) 36.1% Public and other holders 63.5%
HolderTypeShares% of sharesAs of
Chernett Jorey 5%+ holder (13G) 2,339,009 0.29% 2026-08-05
ADAR1 Capital Management, LLC Institution (13G, 5%+) 967,740 0.12% 2026-09-30
Dauntless Investment Group, LLC 5%+ holder (13G) 842,340 0.10% 2026-09-25
Steven R. S. Coffey
Director · +100,000 options
Insider 16,000 0.00% 2026-03-18

Share count 809,418,734 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full KZIA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for KZIA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.